Pure acute erythroleukemia is a rare form of acute myeloid leukemia (AML) with predominant erythroid lineage proliferation. It is a heterogeneous entity amongst AML that can occur at any age, including childhood, and comprises less than 5% of AML. Di Guglielmo reported the original case of acute erythroleukemia in 1917; he described it as a syndrome composed of immature erythroid and myeloid el...

MYC proto-oncogene family including c-myc and n-myc (MYCN) are critical for normal cell development and tumorigenesis. Overexpression of c-myc causes acute erythroleukemia in vivo. However, the role of MYCN in acute erythroleukemia remains poorly understood. In this study, we found that the patients with erythroleukemia showed higher expression of MYCN than normal controls. In vitro experiments...

Pure erythroid leukemia is a rare entity that represents less than 5% of pediatric acute myeloid leukemias and classified according to the World Health Organization (WHO) within group unspecified leukemias. A clinical case 5-year-old patient admitted with septic arthritis in Pediatric Hospital, he also presenting fever anemia, for which medullogram immunophenotype were performed erythroleukemia...

Recent advances in molecular medicine have proposed new therapeutic strategies for cancer. One of the molecular research lines for the diagnosis and treatment of cancer is the use of long non-coding RNAs (LncRNAs) which are a class of non-coding RNA molecules longer than 200 base pairs in length that act as the key regulator of gene expression. Different aspects of cellular activities like cell...

two cases of erythremic myelosis and one case of erythroleukemia in iran erythremic myelosis or di-guglielmo disease is characterized by generalized and systemic proliferation. selectively affecting erythropoietic apparatus and according to the course; there ure acute and chronic forms. thus the condition has much in common with leukemia but depends on a proliferation of erythrocytic series ins...

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 interna...

Pure Erythroid Leukemia (PEL) is an aggressive and exceedingly rare form of acute leukemia. In the 2008 WHO classifi cation PEL was one of the subtypes of acute erythroid leukemia the other subtype being erythroleukemia (erythroid/ myeloid). In the 2016 WHO classifi cation update, erythroleukemia was merged into myelodysplastic syndrome and PEL now is the only type of acute erythroid leukemia.1...

The models of acute erythroleukemia caused in mice by the Friend retrovirus SFFV (spleen focus forming virus) and the Spi-1/PU.1 transgenesis provide considerable information to help to understand the molecular mechanisms underlying the multi-stage nature of leukemia. Leukemogenesis in these murine models is initiated from an acute hyperplasia of erythroid progenitor cells followed later on by ...